Drug prices are a key barrier to healthcare access in the Philippines, where out-of-pocket payments remain the main form of health spending. This study assessed price variations between drug distributor prices for commonly procured medicines in Region 02 and the National Capital Region (NCR), and the national Drug Price Reference Index (DPRI). A cross-sectional survey was conducted from June to December 2023 using 2022 commonly procured medicines from 18 public health facilities in Region 02. Price and availability data of both essential and nonessential medicines were gathered from 50 Food and Drug Administration-registered drug distributors in Region 02 and NCR. The top 15 of the 591 commonly procured medicines were selected for comparison. Six had distributor prices below the DPRI; however, only one (Gliclazide 30 mg tablet) had a statistically significant difference (p < 0.05), with a large effect size (Cohen’s d = −2.90). The remaining five showed small to negligible effect sizes and nonsignificant p-values (p > 0.05). Nine medicines were within the DPRI range but not below the lowest reference price. Three essential medicines, including insulin and two anti-Tuberculosis kits, were available from only a few surveyed distributors, indicating limited access across the network. The findings reveal pricing disparities and highlight gaps in access to critical medicines; hence, continuous price monitoring and support the establishment of a Drug Distributor Price Reference Index are recommended. This is to inform cost-effective and equitable procurement policies.
Chua JMT, Capili JT, Rabanal MAS, Mallabo LAC, Asuncion JEL. Towards a drug distributor price reference index: A 2023 survey of pricing discrepancies for region 02 medicines procured from NCR and local distributors, Philippines. J Appl Pharm Sci. 2025. Article in Press. http://doi.org/10.7324/JAPS.2025.v15.i12.5
1. Lasco G, Yu VG, David CC. The lived realities of health financing: a qualitative exploration of catastrophic health expenditure in the Philippines. Acta Med Philipp. 2020;56(11):5–15. doi: https://doi.org/10.47895/AMP.VI0.2389
2. Rivera JPR. Estimating Gini coefficient and FGT indices in the Philippines using the family income and expenditure survey. J Poverty. 2020;24(7):568–90. doi: https://doi.org/10.1080/10875549.2020.1737300
3. Ball D, Tisocki K. Public procurement prices of medicines in the Philippines. Geneva, Switzerland: World Health Organization; 2009.
4. Ulep VGT, Dela Cruz NAO. Analysis of out-of-pocket expenditures in the Philippines. Quezon City, Philippines: Philippine Institute for Development Studies (PIDS); 2013.
5. Stoll S, Zöttl G. Transparency in buyer-determined auctions: should quality be private or public? Prod Oper Manag. 2017:2;2006–32. doi: https://doi.org/10.1111/POMS.12736
6. Oyegoke AS. Transparency in public procurement: a study of the European Union directive for public works, supply and services contracts. Int J Bus Excell. 2012;5(3):195–219. doi: https://doi.org/10.1504/IJBEX.2012.046639
7. Kumar AA. Comprehensive healthcare system and method for effective management of healthcare services. 2016.
8. Jha P, Ambwani S, Singh S, Bhardwaj P, Varthya SB, Charan J. Availability of the essential medicines is community pharmacies: a cross-sectional study. J Pharmacol Pharmacother. 2022;13(1):92–4. doi: https://doi.org/10.1177/0976500x221080370
9. Bartsch P, Lux T, Wagner A, Gabriel R. E-procurement in hospitals – an integrated supply chain management of pharmaceutical and medical products by the usage of mobile devices. International Conference on Wireless Mobile Communication and Healthcare. Berlin, Heidelberg: Springer Berlin Heidelberg, 2012.
10. Ferrario A, Humbert T, Kanavos P, Pedersen HB. Strategic procurement and international collaboration to improve access to medicines. Bull World Health Organ. 2017;95(10):720–2. doi: https://doi.org/10.2471/BLT.16.187344
11. Seidman G, Atun R. Do changes to supply chains and procurement processes yield cost savings and improve availability of pharmaceuticals, vaccines or health products? A systematic review of evidence from low-income and middle-income countries. BMJ Glob Health. 2017;2(2):e000243. doi: https://doi.org/10.1136/BMJGH-2016-000243
12. Ahmad NS, Makmor-Bakry M, Hatah E. Drug price transparency initiative: a scoping review. Res Social Adm Pharm. 2020;16:1359–69. doi: https://doi.org/10.1016/J.SAPHARM.2020.01.002
13. Khoso I, Ahmed RR, Ahmed J. Pricing strategies in pharmaceutical marketing. Pharma Innov J. 2014;3:13–7.
14. Capri S, Antoñanzas F. Efficiency ratio and rocketing drug prices: old concerns and new possibilities. Eur J Health Econ. 2020;21(9):1273–7. doi: https://doi.org/10.1007/S10198-020-01194-9
15. Mobula LM, Sarfo S, Arthur L, Burnham G, Ansong D, Plange-Rhule J, et al. A novel initiative to improve access to medicines for control of non-communicable diseases in low-and middle- income countries. 2018;2:12. doi: https://doi.org/10.12688/GATESOPENRES.12798.2
16. Lambojon K, Chang J, Saeed A, Hayat K, Li P, Jiang M, et al. Prices, availability and affordability of medicines with value-added tax exemption: a cross-sectional survey in the Philippines. Int J Environ Res Public Health. 2020;17:5242. doi: https://doi.org/10.3390/IJERPH17145242
17. Nuqui HS, Redaniel MT. Retail mark?ups on generic and originator medicines in Philippine pharmacies: evidence from WHO/HAI– 2013 survey. Health Policy Plan. 2015;30(9):1071–9. doi: https://doi.org/10.1093/heapol/czu108
18. Reyes RJ, Tabuga AF. Pharmaceutical market segmentation and price discrimination in the Philippines: the role of branded generics. Philipp Rev Econ. 2018;55(2):45–68. doi: https://doi.org/10.22198/PRE2018/55(2)/45
Year
Month